139 related articles for article (PubMed ID: 21163674)
1. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC).
Panteliadou M; Giatromanolaki A; Touloupidis S; Destouni E; Tsoutsou PG; Pantelis P; Abatzoglou I; Sismanidou K; Koukourakis MI
Urol Oncol; 2012; 30(6):813-20. PubMed ID: 21163674
[TBL] [Abstract][Full Text] [Related]
2. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
Koukourakis MI; Tsolos C; Touloupidis S
Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
[TBL] [Abstract][Full Text] [Related]
3. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy.
Koukourakis MI; Kyrgias G; Panteliadou M; Papadopoulou A; Tsiarkatsi M; Papachristou E; Bebeli M
Am J Clin Oncol; 2013 Aug; 36(4):338-43. PubMed ID: 22643562
[TBL] [Abstract][Full Text] [Related]
5. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
Koukourakis MI; Papadopoulou A; Abatzoglou I; Panteliadou M; Sismanidou K; Touloupidis S
Anticancer Res; 2012 Oct; 32(10):4561-8. PubMed ID: 23060587
[TBL] [Abstract][Full Text] [Related]
6. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience.
Koukourakis MI; Touloupidis S; Manavis J; Abatzoglou I; Sismanidou K; Sivridis L
Anticancer Res; 2004; 24(5B):3239-43. PubMed ID: 15510617
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of efficacy and toxicity in two different hypofractionated 3D-conformal external beam radiotherapy schedules in localised muscle invasive bladder cancer.
Kouloulias V; Mosa E; Tolia M; Kantzou I; Koliarakis N; Platoni K; Georgakopoulos I; Siatelis A; Sarris G; Beli I; Chrisofos M; Kelekis N
J BUON; 2013; 18(4):942-8. PubMed ID: 24344021
[TBL] [Abstract][Full Text] [Related]
8. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.
Koukourakis MI; Abatzoglou I; Sivridis L; Tsarkatsi M; Delidou H
Anticancer Res; 2006; 26(3B):2437-43. PubMed ID: 16821629
[TBL] [Abstract][Full Text] [Related]
9. Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC).
Panteliadou M; Touloupidis S; Giatromanolaki A; Pistevou K; Kyrgias G; Tsoutsou P; Kalaitzis C; Koukourakis MI
Med Oncol; 2011 Dec; 28(4):1356-62. PubMed ID: 20424934
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
Koukourakis MI
Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
13. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study.
Koukourakis MI; Simopoulos C; Pitiakoudis M; Lyratzopoulos N; Romanidis K; Giatromanolaki A; Polychronidis A; Kouklakis G; Sivridis E; Minopoulos G; Manolas K
Anticancer Res; 2008; 28(5B):3035-40. PubMed ID: 19031952
[TBL] [Abstract][Full Text] [Related]
15. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
Koukourakis MI; Panteliadou M; Abatzoglou IM; Sismanidou K; Sivridis E; Giatromanolaki A
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e7-13. PubMed ID: 23040218
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
17. Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder: long term results of a pilot study.
Vikram B; Chadha M; Malamud SC; Hecht H; Grabstald H
Cancer; 1998 Mar; 82(5):918-22. PubMed ID: 9486582
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy.
Cowan RA; McBain CA; Ryder WD; Wylie JP; Logue JP; Turner SL; Van der Voet J; Collins CD; Khoo VS; Read GR
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):197-207. PubMed ID: 15093917
[TBL] [Abstract][Full Text] [Related]
20. Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy.
Koukourakis MI; Kyrgias G; Papadopoulou A; Panteliadou M; Giatromanolaki A; Sivridis E; Mavropoulou S; Kalogeris K; Nassos P; Milioudis N; Touloupidis S
Anticancer Res; 2011 May; 31(5):1745-51. PubMed ID: 21617234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
